IP Library › Granted Patent US 12,514,267
Granted Patent B2
US 12,514,267 · App. 18/137,740 · Granted Jan 6, 2026

Oligosaccharide compositions for use as animal feed and methods of producing thereof

Inventors: John M. Geremia (Watertown, MA); Raffi Mardirosian (Cambridge, MA); Michael J. Gidding (Cambridge, MA); Anastasia V. Murphy (Attleborough, MA)
Assignee: DSM Nutritional Products, LLC
A23K20/163A23K20/142A23K20/147A23K20/195A23K20/22A23K20/24A23K20/26A23K50/30A23K50/75A61K31/702A61K45/06Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,267
App. No.
18/137,740
Granted
Jan 6, 2026
Kind
B2
Abstract

Described herein are methods of producing animal feed made up of oligosaccharide compositions, as well as methods of producing such oligosaccharide compositions and animal feed compositions, and methods of using such animal feed compositions to enhance animal growth.

Claims (109)

1 . An animal feed composition, comprising:

(i) a base feed, and

(ii) an oligosaccharide composition,

wherein the oligosaccharide composition has a glycosidic bond type distribution of:

1 to 30 mol % α-(1,3) glycosidic linkages; and

1 to 20 mol % β-(1,3) glycosidic linkages; and

at least 15 mol % β-(1,2) glycosidic linkages;

wherein at least 10 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3; and

wherein the oligosaccharide composition is in an effective amount to (i) reduce feed conversion ratio (FCR) between 1 and 30%, (ii) increase average daily weight gain between 1 and 30%; and/or (iii) increase average daily feed intake between 1 and 30%.

2 . The animal feed composition of claim 1 , wherein the oligosaccharide composition has a glycosidic bond type distribution of less than 9 mol % α-(1,4) glycosidic linkages, and less than 19 mol % α-(1,6) glycosidic linkages.

3 . An animal feed composition, comprising:

The animal feed composition of claim 1 , wherein

the oligosaccharide composition has a glycosidic bond type distribution of:

less than 9 mol % α-(1,4) glycosidic linkages; and

less than 19 mol % α-(1,6) glycosidic linkages, and

wherein at least 10 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3.

4 . The animal feed composition of claim 1 , wherein the oligosaccharide composition is present in the animal feed composition at below 5,000 ppm by weight as a dry oligosaccharide composition of the animal feed composition.

5 . The animal feed composition of claim 1 , wherein the base feed comprises:

1200 to 1600 cal/lb apparent metabolizable energy;

16 to 24 wt % crude protein;

1.0 to 1.4 wt % lysine;

0.5 to 0.75 wt % methionine;

0.75 to 1.1 wt % total sulfur amino acids;

0.7 to 1.0 wt % calcium;

0.35 to 0.5 wt % total available phosphorous; and

0.15 to 0.3 wt % sodium.

6 . The animal feed composition of claim 1 , wherein the oligosaccharide composition comprises a gluco-oligosaccharide, a galacto-oligosaccharide, a fructo-oligosaccharide, a manno-oligosaccharide, an arabino-oligosaccharide, a xylo-oligosaccharide, a gluco-galacto-oligosaccharide, a gluco-fructo-oligosaccharide, a gluco-manno-oligosaccharide, a gluco-arabino-oligosaccharide, a gluco-xylo-oligosaccharide, a galacto-fructo-oligosaccharide, a galacto-manno-oligosaccharide, a galacto-arabino-oligosaccharide, a galacto-xylo-oligosaccharide, a fructo-manno-oligosaccharide, a fructo-arabino-oligosaccharide, a fructo-xylo-oligosaccharide, a manno-arabino-oligosaccharide, a manno-xylo-oligosaccharide, an arabino-xylo-oligosaccharide, or a xylo-gluco-galacto-oligosaccharide, or any combinations thereof.

7 . The animal feed composition of claim 1 , wherein the oligosaccharide composition has a glycosidic bond type distribution of:

0 to 20 mol % α-(1,2) glycosidic linkages;

15 to 45 mol % β-(1,2) glycosidic linkages;

1 to 30 mol % α-(1,3) glycosidic linkages;

1 to 20 mol % β-(1,3) glycosidic linkages;

0 to 55 mol % β-(1,4) glycosidic linkages; and

10 to 55 mol % β-(1,6) glycosidic linkages.

8 . The animal feed composition of claim 1 , wherein at least 50 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3.

9 . The animal feed composition of claim 1 , wherein the animal is poultry, and wherein the animal feed composition is poultry feed.

10 . The animal feed composition of claim 9 , wherein the poultry feed:

(i) reduces feed conversion ratio (FCR) between 1 to 10%; or

(ii) increases average daily weight gain between 1 to 10%; or

(iii) increases average daily feed intake between 1 to 10%; or

any combination of (i), (ii), and (iii),

when fed to poultry as compared to poultry fed a feed composition without the oligosaccharide composition.

11 . The animal feed composition of claim 9 , wherein the poultry suffers from a disease or disorder, or is raised in a challenged environment.

12 . The animal feed composition of claim 11 , wherein the poultry feed:

(i) reduces feed conversion ratio (FCR) between 1 to 30%; or

(ii) increases average daily weight gain between 1 to 30%; or

(iii) increases average daily feed intake between 1 to 30%; or

any combination of (i), (ii), and (iii),

when fed to poultry as compared to poultry fed a feed composition without the oligosaccharide composition.

13 . The animal feed composition of claim 1 , wherein the animal is swine, and the animal feed composition is swine feed.

14 . An animal feed pre-mix, comprising:

(i) a carrier material; and

(ii) an oligosaccharide composition of claim 1 .

15 . The animal feed pre-mix of claim 14 , wherein the oligosaccharide composition has a glycosidic bond type distribution of less than 9 mol % α-(1,4) glycosidic linkages, and less than 19 mol % α-(1,6) glycosidic linkages.

16 . An animal feed pre-mix, comprising:

(i) a carrier material; and

(ii) the oligosaccharide composition of claim 3 ,

wherein the oligosaccharide composition has a glycosidic bond type distribution of:

less than 9 mol % α-(1,4) glycosidic linkages; and

less than 19 mol % α-(1,6) glycosidic linkages, and

wherein at least 10 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3.

17 . The animal feed pre-mix of claim 14 , wherein the oligosaccharide composition has a glycosidic bond type distribution of 15 to 45 mol % β-(1,2) glycosidic linkages.

18 . The animal feed pre-mix of claim 14 , wherein at least 50 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3.

19 . The animal feed pre-mix of claim 14 , wherein the animal is poultry, and wherein the animal feed is poultry feed.

20 . An animal feed composition, comprising (i) a base feed and (ii) the animal feed pre-mix of claim 14 .

21 . A method of enhancing growth of an animal, comprising:

providing feed to the animal, wherein the feed comprises:

(i) a base feed; and

(ii) an oligosaccharide composition of claim 1 ,

thereby enhancing growth of the animal.

22 . A method of decreasing feed conversion ratio of feed provided to an animal, comprising:

providing feed to the animal, wherein the feed comprises:

(i) a base feed; and

(ii) an oligosaccharide composition of claim 1 , thereby decreasing the feed conversion ratio of feed provided to the animal.

23 . The method of claim 22 , wherein the feed conversion ratio is between 0 to 4% higher than the performance target minimum.

24 . The method of claim 22 , wherein the feed conversion ratio is decreased between 1 to 10% as compared to an animal provided feed without the oligosaccharide composition.

25 . The method of claim 22 , wherein the animal has a disease or disorder, or is raised in a challenged environment.

26 . The method of claim 25 , wherein the disease or disorder is necrotic enteritis, coccidiosis, nutrient malabsorption syndrome, intestinal barrier breakdown, colisepticemia, yolk sack infection, salmonella infection, or campylobacter infection.

27 . The method of claim 21 , wherein the animal is poultry.

28 . The method of claim 25 , wherein the feed conversion ratio is decreased between 1 to 30% as compared to an animal provided feed without the oligosaccharide composition.

29 . A method of enhancing growth of an animal population, comprising:

feeding to the animal population an animal feed,

wherein the animal feed comprises an oligosaccharide composition at an inclusion rate of less than 5,000 ppm wt % as a dry oligosaccharide composition per weight of animal feed;

wherein the oligosaccharide composition has a glycosidic bond type distribution of:

at least 1 mol % α-(1,3) glycosidic linkages; and

at least 1 mol % β-(1,3) glycosidic linkages, and

wherein at least 10 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3and wherein the oligosaccharide composition is in an effective amount to (i) reduce feed conversion ratio (FCR) between 1 and 30%, (ii) increase average daily weight gain between 1 and 30%; and/or (iii) increase average daily feed intake between 1 and 30%; thereby enhancing growth of the animal population.

30 . The method of claim 29 , wherein the oligosaccharide composition has a glycosidic bond type distribution of at least 15 mol % β-(1,2) glycosidic linkages.

31 . The method of claim 29 , wherein the animal population is monogastric.

32 . The method of claim 29 , wherein the animal feed comprises the oligosaccharide composition at an inclusion rate of less than 3,000 ppm wt % as a dry oligosaccharide composition per weight of animal feed.

33 . The method of claim 29 , wherein the animal population has a disease or disorder, or is raised in a challenged environment.

34 . The method of claim 33 , wherein the disease or disorder is necrotic enteritis, coccidiosis, nutrient malabsorption syndrome, intestinal barrier breakdown, colisepticemia, yolk sack infection, salmonella infection, or campylobacter infection.

35 . The method of claim 29 , wherein the animal population is a poultry population, wherein the feed conversion ratio is decreased between 1 to 30% as compared to an animal population provided feed without the oligosaccharide composition.

36 . The method of claim 29 , wherein the animal population is a swine population, wherein the feed conversion ratio is decreased between 1 to 10% as compared to an animal population provided feed without the oligosaccharide composition.

37 . A method of treating an animal having necrotic enteritis, said method comprising administering the oligosaccharide composition to the animal in need thereof, wherein the oligosaccharide composition has a glycosidic bond type distribution of:

at least 10 mol % α-(1,3) glycosidic linkages; and

at least 10 mol % β-(1,3) glycosidic linkages,

wherein at least 10 dry wt % of the oligosaccharide composition has a degree of polymerization of at least 3 and wherein the oligosaccharide composition is in an effective amount to (i) reduce feed conversion ratio (FCR) between 1 and 30%, (ii) increase average daily weight gain between 1 and 30%; and/or (iii) increase average daily feed intake between 1 and 30% , thereby treating an animal having necrotic enteritis.

38 . The method of claim 37 , wherein the method decreases feed conversion ratio, improve weight gain, enhance growth, increases digestibility of provided feed, increases released nutrients from provided feed, and/or reduces mortality rate of the animal.

39 . The method of claim 37 , wherein the feed conversion ratio is between 0 to 4% higher than the performance target minimum.

40 . The method of claim 37 , wherein the feed conversion ratio is decreased between 1 to 10% as compared to an animal provided feed without the oligosaccharide composition.

41 . The method of claim 37 , wherein the feed conversion ratio is decreased between 1 to 30% as compared to an animal provided feed without the oligosaccharide composition.

42 . The method of claim 37 , wherein the animal is a bird, a pig, a fish or a cow.

43 . The method of claim 38 , wherein the animal is a poultry and the weight gain of the poultry is a daily weight gain of at least 20 grams per day, at least 30 grams per day, at least 40 grams per day, at least 50 grams per day, at least 60 grams per day, at least 70 grams per day, at least 80 grams per day, at least 90 grams per day, between 20 to 100 grams per day, between 20 to 80 grams per day, between 30 to 50 grams per day, between 40 to 60 grams per day, between 50 to 70 grams per day, or between 70 to 90 grams per day.

44 . The method of claim 37 , wherein the animal is monogastric.

45 . The method of claim 37 , wherein the animal having necrotic enteritis is a bird and is challenged by Clostridium perfringens.

46 . The method of claim 37 , wherein the oligosaccharide composition is present in an animal feed, optionally wherein the animal feed further comprises a base feed.

47 . The method of claim 46 , wherein the oligosaccharide composition is present in the animal feed at an inclusion rate of at least 50 ppm, 70, 100, 150, 200, 300, 400, 500, 600, 700, 800, or 900 ppm.

48 . The method of claim 47 , wherein the oligosaccharide composition is present in the feed at below 5,000 ppm, below 3,000 ppm, between 10 to 1,000 ppm, or between 10 to 500 ppm weight as a dry oligosaccharide composition per weight of the feed.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: HERCULES CAPITAL, INC.
To: DSM NUTRITIONAL PRODUCTS, LLC
Reel/Frame 071406/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: MIDORI USA, INC.
To: CADENA BIO, INC.
Reel/Frame 071406/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: CADENA BIO, INC.
To: HERCULES CAPITAL, INC.
Reel/Frame 071406/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: GEREMIA, JOHN M.; MARDIROSIAN, RAFFI; GIDDING, MICHAEL J.; MURPHY, ANASTASIA V.
To: MIDORI USA, INC.
Reel/Frame 071406/0438 →
Continuity (8)
Division 17106617 · Nov 30, 2020
Continuation 14995129 · Jan 13, 2016
Provisional Application 62255343 · Nov 13, 2015
Provisional Application 62255341 · Nov 13, 2015
Provisional Application 62216945 · Sep 10, 2015
Provisional Application 62216952 · Sep 10, 2015
Provisional Application 62108037 · Jan 26, 2015
Related Publication 20230255240A1 · Aug 17, 2023
References Cited (345)
US 2027904A · Farber · 1936 [cited by applicant]
US 2436967A · Leuck · 1948 [cited by applicant]
US 2719179A · Mora et al. · 1955 [cited by applicant]
US 3766165A · Rennhard · 1973 [cited by applicant]
US 3876794A · Rennhard · 1975 [cited by applicant]
US 3973049A · Furda et al. · 1976 [cited by applicant]
US 4761401A · Couchman et al. · 1988 [cited by applicant]
US 4841041A · van Boeckel et al. · 1989 [cited by applicant]
US 4847338A · Linhardt et al. · 1989 [cited by applicant]
US 4927811A · Quarles · 1990 [cited by applicant]
US 4965354A · Yanaki et al. · 1990 [cited by applicant]
US 5051500A · Elmore · 1991 [cited by applicant]
US 5280111A · Shoji et al. · 1994 [cited by applicant]
US 5424418A · Duflot · 1995 [cited by applicant]
US 5556899A · Afzali-Ardakani et al. · 1996 [cited by applicant]
US 5558899A · Kuzee et al. · 1996 [cited by applicant]
US 5573794A · Duflot · 1996 [cited by applicant]
US 5580762A · Karube et al. · 1996 [cited by applicant]
US 5645647A · Guzek et al. · 1997 [cited by applicant]
US 5780620A · Mandai et al. · 1998 [cited by applicant]
US 5843922A · Whistler et al. · 1998 [cited by applicant]
US 5976580A · Ivey et al. · 1999 [cited by applicant]
US 6423833B1 · Catani et al. · 2002 [cited by applicant]
US 6475552B1 · Shah et al. · 2002 [cited by applicant]
US 6559302B1 · Shah et al. · 2003 [cited by applicant]
US 6638916B1 · Cowden et al. · 2003 [cited by applicant]
US 6677142B1 · Weissmuller et al. · 2004 [cited by applicant]
US 7608291B2 · Baillon et al. · 2009 [cited by applicant]
US 7608436B2 · Harrison et al. · 2009 [cited by applicant]
US 7615365B2 · Caimi et al. · 2009 [cited by applicant]
US 8057840B2 · Harrison et al. · 2011 [cited by applicant]
US 8148505B2 · Ando et al. · 2012 [cited by applicant]
US 8227448B2 · Van Laere et al. · 2012 [cited by applicant]
US 8445460B2 · Deremaux et al. · 2013 [cited by applicant]
US 8466242B2 · Geremia et al. · 2013 [cited by applicant]
US 8476388B2 · Geremia et al. · 2013 [cited by applicant]
US 8591919B2 · Stahl et al. · 2013 [cited by applicant]
US 8741376B2 · Broekaert et al. · 2014 [cited by applicant]
US 8835403B2 · Geng et al. · 2014 [cited by applicant]
US 8993039B2 · Harrison et al. · 2015 [cited by applicant]
US 9079171B2 · Geremia et al. · 2015 [cited by applicant]
US 9169506B2 · Caimi et al. · 2015 [cited by applicant]
US 9205418B2 · Geremia et al. · 2015 [cited by applicant]
US 9238845B2 · Baynes et al. · 2016 [cited by applicant]
US 9492473B2 · von Maltzahn et al. · 2016 [cited by applicant]
US 9757403B2 · von Maltzahn et al. · 2017 [cited by applicant]
US 9783619B2 · Bureau et al. · 2017 [cited by applicant]
US 9801403B2 · Krüger · 2017 [cited by applicant]
US 9901595B2 · von Maltzahn et al. · 2018 [cited by applicant]
US 10131721B2 · Geremia et al. · 2018 [cited by applicant]
US 10314853B2 · von Maltzahn et al. · 2019 [cited by applicant]
US 10702542B2 · von Maltzahn et al. · 2020 [cited by applicant]
US 10752705B2 · Geremia et al. · 2020 [cited by applicant]
US 10787527B2 · Geremia et al. · 2020 [cited by applicant]
US 10849337B2 · Geremia · 2020 [cited by examiner]
US 10881676B2 · von Maltzahn et al. · 2021 [cited by applicant]
US 10894057B2 · von Maltzahn et al. · 2021 [cited by applicant]
US 11169101B2 · Liu et al. · 2021 [cited by applicant]
US 11229660B2 · von Maltzahn et al. · 2022 [cited by applicant]
US 11584805B2 · Geremia et al. · 2023 [cited by applicant]
US 11697692B2 · Geremia et al. · 2023 [cited by applicant]
US 11883422B2 · von Maltzahn et al. · 2024 [cited by applicant]
US 20030162300A1 · Kunz et al. · 2003 [cited by applicant]
US 20040220389A1 · Buchwald et al. · 2004 [cited by applicant]
US 20040235789A1 · Day et al. · 2004 [cited by applicant]
US 20050004070A1 · Stahl et al. · 2005 [cited by applicant]
US 20050075311A1 · Lane · 2005 [cited by applicant]
US 20060008574A1 · Begli et al. · 2006 [cited by applicant]
US 20060014717A1 · Angstrom et al. · 2006 [cited by applicant]
US 20060051812A1 · Helin et al. · 2006 [cited by applicant]
US 20060067947A1 · Yagita · 2006 [cited by applicant]
US 20060127448A1 · Carlson et al. · 2006 [cited by applicant]
US 20060263415A1 · Sedmak · 2006 [cited by examiner]
US 20070036840A1 · Tuduri et al. · 2007 [cited by applicant]
US 20070048432A1 · Holzgraefe et al. · 2007 [cited by applicant]
US 20070148728A1 · Johnson et al. · 2007 [cited by applicant]
US 20070254848A1 · Geng et al. · 2007 [cited by applicant]
US 20080051573A1 · Hirth et al. · 2008 [cited by applicant]
US 20080069861A1 · Brown et al. · 2008 [cited by applicant]
US 20090098240A1 · Mills et al. · 2009 [cited by applicant]
US 20090304852A1 · Hopkins et al. · 2009 [cited by applicant]
US 20100069327A1 · Van De Heijning et al. · 2010 [cited by applicant]
US 20100239584A1 · Mulard et al. · 2010 [cited by applicant]
US 20100284972A1 · Naeye et al. · 2010 [cited by applicant]
US 20110052538A1 · Brown et al. · 2011 [cited by applicant]
US 20110250235A1 · Saarinen et al. · 2011 [cited by applicant]
US 20110306757A1 · Lopez-Belmonte Encina et al. · 2011 [cited by applicant]
US 20120034366A1 · Hoffman et al. · 2012 [cited by applicant]
US 20120041189A1 · Clavel et al. · 2012 [cited by applicant]
US 20120220740A1 · Geremia et al. · 2012 [cited by applicant]
US 20120252957A1 · Geremia et al. · 2012 [cited by applicant]
US 20130005684A1 · Fichert et al. · 2013 [cited by applicant]
US 20130028869A1 · Bruggeman et al. · 2013 [cited by applicant]
US 20130042859A1 · Geremia et al. · 2013 [cited by applicant]
US 20130216693A1 · Harrison et al. · 2013 [cited by applicant]
US 20130233308A1 · Geremia et al. · 2013 [cited by applicant]
US 20140060522A1 · Baynes et al. · 2014 [cited by applicant]
US 20140105864A1 · Di Leo · 2014 [cited by applicant]
US 20140187474A1 · Sonnenburg · 2014 [cited by applicant]
US 20140234912A1 · Dekany et al. · 2014 [cited by applicant]
US 20140335131A1 · Mazmanian et al. · 2014 [cited by applicant]
US 20150087616A1 · Ritter et al. · 2015 [cited by applicant]
US 20150202607A1 · Geremia et al. · 2015 [cited by applicant]
US 20150238948A1 · Geremia · 2015 [cited by applicant]
US 20150352133A1 · Jennewein · 2015 [cited by applicant]
US 20160007642A1 · Geremia et al. · 2016 [cited by applicant]
US 20160015065A1 · Sumner et al. · 2016 [cited by applicant]
US 20160032038A1 · Baynes et al. · 2016 [cited by applicant]
US 20160122447A1 · Geremia et al. · 2016 [cited by applicant]
US 20160213702A1 · von Maltzahn et al. · 2016 [cited by applicant]
US 20170151268A1 · von Maltzahn et al. · 2017 [cited by applicant]
US 20170151269A1 · von Maltzahn et al. · 2017 [cited by applicant]
US 20170246201A1 · von Maltzahn et al. · 2017 [cited by applicant]
US 20180000145A1 · Geremia et al. · 2018 [cited by applicant]
US 20180000146A1 · Geremia · 2018 [cited by applicant]
US 20180037599A1 · Duflot et al. · 2018 [cited by applicant]
US 20180147221A1 · von Maltzahn et al. · 2018 [cited by applicant]
US 20180147222A1 · von Maltzahn et al. · 2018 [cited by applicant]
US 20180235987A1 · von Maltzahn et al. · 2018 [cited by applicant]
US 20180296582A1 · von Maltzahn et al. · 2018 [cited by applicant]
US 20190062468A1 · Geremia et al. · 2019 [cited by applicant]
US 20190091249A1 · von Maltzahn et al. · 2019 [cited by applicant]
US 20190209600A1 · Gubler · 2019 [cited by applicant]
US 20190290675A1 · Gibson et al. · 2019 [cited by applicant]
US 20190307159A1 · Geremia et al. · 2019 [cited by applicant]
US 20200000831A1 · Geremia et al. · 2020 [cited by applicant]
US 20200009168A1 · von Maltzahn et al. · 2020 [cited by applicant]
US 20200093845A1 · Von Maltzahn et al. · 2020 [cited by applicant]
US 20200093851A1 · von Maltzahn et al. · 2020 [cited by applicant]
US 20200352980A1 · Mahowald et al. · 2020 [cited by applicant]
US 20200354481A1 · Geremia et al. · 2020 [cited by applicant]
US 20200390798A1 · Gibson et al. · 2020 [cited by applicant]
US 20210002387A1 · Geremia et al. · 2021 [cited by applicant]
US 20210076705A1 · Geremia et al. · 2021 [cited by applicant]
US 20210113596A1 · von Maltzahn et al. · 2021 [cited by applicant]
US 20210121486A1 · Geremia et al. · 2021 [cited by applicant]
US 20210137956A1 · von Maltzahn et al. · 2021 [cited by applicant]
US 20210137964A1 · von Maltzahn et al. · 2021 [cited by applicant]
US 20210161942A1 · von Maltzahn et al. · 2021 [cited by applicant]
US 20210164926A1 · Liu et al. · 2021 [cited by applicant]
US 20210198302A1 · Liu et al. · 2021 [cited by applicant]
US 20210352945A1 · Geremia · 2021 [cited by applicant]
US 20210401861A1 · von Maltzahn et al. · 2021 [cited by applicant]
US 20220000891A1 · Blokker et al. · 2022 [cited by applicant]
US 20220233560A1 · Yatsunenko et al. · 2022 [cited by applicant]
US 20220233577A1 · Gibson et al. · 2022 [cited by applicant]
US 20220395521A1 · von Maltzahn et al. · 2022 [cited by applicant]
US 20220400728A1 · Geremia et al. · 2022 [cited by applicant]
US 20220409644A1 · Geremia et al. · 2022 [cited by applicant]
US 20230113218A1 · Mahowald et al. · 2023 [cited by applicant]
US 20230123695A1 · von Maltzahn et al. · 2023 [cited by applicant]
US 20230165881A1 · Lawrence et al. · 2023 [cited by applicant]
US 20230255240A1 · Geremia et al. · 2023 [cited by applicant]
US 20230255989A1 · von Maltzahn et al. · 2023 [cited by applicant]
US 20230277573A1 · Millet et al. · 2023 [cited by applicant]
US 20240108642A1 · von Maltzahn et al. · 2024 [cited by applicant]
CA 2420247A1 · 2002 [cited by applicant]
CA 2511190A1 · 2004 [cited by applicant]
CA 2805501A1 · 2012 [cited by applicant]
CA 2616065C · 2012 [cited by applicant]
CA 2818505A1 · 2012 [cited by applicant]
CA 2827294A1 · 2012 [cited by applicant]
CA 2833311A1 · 2012 [cited by applicant]
CA 2581487C · 2013 [cited by applicant]
CN 1600146A · 2005 [cited by applicant]
CN 1731938A · 2006 [cited by applicant]
CN 102459605A · 2012 [cited by applicant]
CN 102892303A · 2013 [cited by applicant]
CN 104171365A · 2014 [cited by applicant]
EA 11417B1 · 2009 [cited by applicant]
EP 0549478A1 · 1993 [cited by applicant]
EP 1634599A1 · 2006 [cited by applicant]
EP 1886696A1 · 2008 [cited by applicant]
EP 1887017A1 · 2008 [cited by applicant]
EP 2138048A1 · 2009 [cited by applicant]
EP 2248907A1 · 2010 [cited by applicant]
EP 2386563A1 · 2011 [cited by applicant]
EP 2401925A1 · 2012 [cited by applicant]
EP 2666788A1 · 2013 [cited by applicant]
ES 2304223B2 · 2009 [cited by applicant]
JP H06121693A · 1994 [cited by applicant]
JP H10316740A · 1998 [cited by applicant]
JP 200186999A · 2001 [cited by applicant]
JP 2003516757A · 2003 [cited by applicant]
JP 2004182628A · 2004 [cited by applicant]
JP 2008081501A · 2008 [cited by applicant]
JP 4597630B2 · 2010 [cited by applicant]
JP 2011501670A · 2011 [cited by applicant]
JP 2011212386A · 2011 [cited by applicant]
JP 2012158526A · 2012 [cited by applicant]
JP 2014513985A · 2014 [cited by applicant]
JP 2014205704A · 2014 [cited by applicant]
RU 2153503C2 · 2000 [cited by applicant]
RU 2509477C1 · 2014 [cited by applicant]
WO WO8705330A1 · 1987 [cited by applicant]
WO WO1995008557A1 · 1995 [cited by applicant]
WO WO2001044489A2 · 2001 [cited by applicant]
WO WO2004026341A1 · 2004 [cited by applicant]
WO WO2004052121A1 · 2004 [cited by applicant]
WO WO2005003329A1 · 2005 [cited by applicant]
WO WO2006041930A2 · 2006 [cited by applicant]
WO WO2007010084A2 · 2007 [cited by applicant]
WO WO2008037839A1 · 2008 [cited by applicant]
WO WO2008156354A1 · 2008 [cited by applicant]
WO WO2009051977A1 · 2009 [cited by applicant]
WO WO2009059283A1 · 2009 [cited by applicant]
WO WO2009082214A1 · 2009 [cited by applicant]
WO WO2010105207A1 · 2010 [cited by applicant]
WO WO2010143961A1 · 2010 [cited by applicant]
WO WO2011008086A1 · 2011 [cited by applicant]
WO WO2011016866A1 · 2011 [cited by applicant]
WO WO2011101002A2 · 2011 [cited by applicant]
WO WO2011134802A1 · 2011 [cited by applicant]
WO WO2012076321A1 · 2012 [cited by applicant]
WO WO2012118767A1 · 2012 [cited by applicant]
WO WO2012127410A1 · 2012 [cited by applicant]
WO WO2012156897A1 · 2012 [cited by applicant]
WO WO2014031956A1 · 2014 [cited by applicant]
WO WO2014032004A1 · 2014 [cited by applicant]
WO WO2014043708A1 · 2014 [cited by applicant]
WO WO2014145276A1 · 2014 [cited by applicant]
WO WO2014159558A1 · 2014 [cited by applicant]
WO WO2014186358A2 · 2014 [cited by applicant]
WO WO2015099755A1 · 2015 [cited by applicant]
WO WO2016007778A1 · 2016 [cited by applicant]
WO WO2016122884A1 · 2016 [cited by applicant]
WO WO2016122885A1 · 2016 [cited by applicant]
WO WO2016122887A1 · 2016 [cited by applicant]
WO WO2016122940A1 · 2016 [cited by applicant]
WO WO2016122889A1 · 2016 [cited by applicant]
WO WO2016172658A2 · 2016 [cited by applicant]
WO WO2016172657A2 · 2016 [cited by applicant]
WO WO2017035412A1 · 2017 [cited by applicant]
WO WO2017083520A1 · 2017 [cited by applicant]
WO WO2018013871A1 · 2018 [cited by applicant]
WO WO2018106845A1 · 2018 [cited by applicant]
WO WO2019014645A1 · 2019 [cited by applicant]
WO WO2019090180A1 · 2019 [cited by applicant]
WO WO2019090181A1 · 2019 [cited by applicant]
WO WO2019090182A2 · 2019 [cited by applicant]
WO WO2020041531A2 · 2020 [cited by applicant]
WO WO2020097568A2 · 2020 [cited by applicant]
WO WO2020097446A1 · 2020 [cited by applicant]
WO WO2020227689A1 · 2020 [cited by applicant]
WO WO2021222660A1 · 2021 [cited by applicant]
WO WO2022016105A1 · 2022 [cited by applicant]
WO WO2022067131A1 · 2022 [cited by applicant]
WO WO2023059530A1 · 2023 [cited by applicant]
WO WO2024023198A1 · 2024 [cited by applicant]
Lesage et al. Cell Wall Assembly in [cited by examiner]
Ballou CE. Isolation, Characterization, and Properties of [cited by examiner]
Bonet et al. Prebiotic effect of yacon ( [cited by examiner]
Abd El-Hack et al. “Necrotic enteritis in broiler chickens: disease characteristics and prevention using organic antibiotic alternatives—a comprehensive review,” Poult Sci. 101(2) (Feb. 2022) (23 pages). [cited by applicant]
Collier et al. “Coccidia-induced mucogenesis promotes the onset of necrotic enteritis by supporting Clostridium perfringens growth,” Vet Immunol Immunopathol.122(1-2):104-15 (Mar. 2008). [cited by applicant]
Dua et al., “Characterization of lacto-N-hexaose and two fucosylated derivatives from human milk by high-performance liquid chromatography and proton NMR spectroscopy,” J Chromatogr. 328:259-69 (1985). [cited by applicant]
Guerin-Deremaux et al., “Effects of a soluble dietary fibre NUTRIOSE® on colonic fermentation and excretion rates in rats,” Nutr Res Pract. 4(6):470-6 (2010). [cited by applicant]
Harris et al., “Impact of Glycosidic Bond Configuration on Short Chain Fatty Acid Production from Model Fermentable Carbohydrates by the Human Gut Microbiota,” Nutrients. 9(1):26 (Jan. 2007) (11 pages). [cited by applicant]
Ning et al., “Synthesis of ß-(1 →6)-branched ß-(1 →3) glucohexaose and its analogues containing an α-(1 →3) linked bond with antitumor activity,” Bioorg Med Chem 11(10):2193-2203 (May 2003). [cited by applicant]
“Dictionary of Starch Science,” Asakura Publishing Co., Ltd. 446-451 (2003) (5 pages). [cited by applicant]
“Generally Recognized as Safe (GRAS) Determination for the Addition of Polydextrose to Infant Formula as a Prebiotic Ingredient In Combination with Galactooligosaccharides,” Aug. 2007 (115 pages). [cited by applicant]
“Thalidomide,” Wikipedia, https://en.wikipedia.org/wiki/Thalidomide#Contraindications, retrieved Sep. 15, 2023 (21 pages). [cited by applicant]
Adamberg et al., “Degradation of fructans and production of propionic acid by [cited by applicant]
Adeniji, “Effects of dietary grit inclusion on the utilization of rice husk by pullet chicks,” Tropical and Subtropical Agroecosystems. 12(1):175-180 (2010). [cited by applicant]
ADM/Matsutani LLC, “Fibersol-LQ Data Information Sheet”, retrieved from <www.Fibersol2.com> (1 page), (retrieved in year 2021). [cited by applicant]
Aggrawal et al., “Technical Application Note 1151. Profiling galactosyloligosaccharide-containing samples by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD),” ThermoFisher Sc… [cited by applicant]
Ahmad et al., “Chapter 11: Beta-Glucan as a Food Ingredient”, [cited by applicant]
Aida et al., “Mushroom as a potential source of prebiotics: a review,” Trends in Food Science & Technology. 20(11-12):567-75 (2009). [cited by applicant]
Archer Daniels Midland Company, “ADM Ingredients Catalog,” pp. I-32 (2016) (36 pages). [cited by applicant]
Ballongue et al., “Effects of Lactulose and Lactitol on Colonic Microflora and Enzymatic Activity,” Scandinavian Journal. 222:41-44 (1997) (4 pages). [cited by applicant]
Bergstrom et al., “Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice,” Gastroenterology. 151(1):152-64 (Jul. 2016) (24 pages). [cited by applicant]
Brookes et al. “Odour character differences for enantiomers correlate with molecular flexibility,” J R Soc Interface. 6(30):75-86 (Jan. 6, 2009). [cited by applicant]
Caligur et al., “Glycobiology: glycosaminoglycans and polysaccharides,” BioFiles. 3(10):1-26 (2008) (28 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 16743842.3, dated Aug. 4, 2020 (5 pages). [cited by applicant]
Coudray et al., “Effects of inulin-type fructans of different chain length and type of branching on intestinal absorption and balance of calcium and magnesium in rats,” Eur J Nutr. 42(2):91-8 (2003). [cited by applicant]
Coulier et al., “In-depth characterization of prebiotic galacto-oligosaccharides by a combination of analytical techniques,” J Agric Food Chem. 57(18):8488-95 (2009). [cited by applicant]
Courtin et al., “Dietary inclusion of wheat bran arabinoxylooligosaccharides induces beneficial nutritional effects in chickens,” Cereal Chem. 85(5):607-13 (2008). [cited by applicant]
Courtin et al., “Effects of dietary inclusion of xylooligosaccharides, arabinoxylooligosaccharides and soluble arabinoxylan on the microbial composition of caecal contents of chickens,” J Sci Food Agric. 88(14):2517-22 … [cited by applicant]
Cummings et al., “Carbohydrate terminology and classification,” Eur J Clin Nutr. 61 (Suppl 1):S5-18 (2007). [cited by applicant]
Cummings et al., “Gastrointestinal Effects of Prebiotics,” Br J Nutr. 87 Suppl 2:S145-51, DOI: 10.1079/BJN/2002530 (2002). [cited by applicant]
Deng et al., “Effect of dietary fiber on intestinal barrier function of 5-Fu stressed rats,” Res Exp Med (Berf). 199(2):111-9 (1999). [cited by applicant]
Dutton et al., “The constitution of a synthetic xylan,” Can J Chem. 40(8):1479-82 (1962). [cited by applicant]
Examination Report for Indian Patent Application No. 201717026993, mailed Aug. 24, 2020 (7 pages). [cited by applicant]
Examination Report for Indonesian Patent Application No. P00201700913, dated Feb. 5, 2020 (4 pages). [cited by applicant]
Extended European Search Report for European Application No. 16743841.5, mailed Jul. 13, 2018 (10 pages). [cited by applicant]
Extended European Search Report for European Application No. 16743842.3, mailed Jul. 9, 2018 (13 pages). [cited by applicant]
Extended European Search Report for European Application No. 16743843.1, mailed Jun. 6, 2018 (8 pages). [cited by applicant]
Extended European Search Report for European Application No. 17206409.9, mailed Jun. 21, 2018 (8 pages). [cited by applicant]
Extended European Search Report for European Application No. 19191223.7, mailed Feb. 17, 2020 (7 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 22207451.0, dated May 8, 2023 (13 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 231525141.8, dated May 4, 2023 (14 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 15819734.3, mailed Feb. 7, 2018 (12 pages). [cited by applicant]
Fasina et al., “Comparative efficacy of a yeast product and bacitracin methylene disalicylate in enhancing early growth and intestinal maturation in broiler chicks from breeder hens of different ages,” Poult Sci. 90(5):… [cited by applicant]
Fetzer et al., “Effect of acid and heat on dextrose and dextrose polymers,” Ind Eng Chem. 45(5):1075-83 (1953). [cited by applicant]
Final Office Action for U.S. Appl. No. 14/795,720, mailed Dec. 28, 2017 (16 pages). [cited by applicant]
First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 15/385,331, mailed Apr. 17, 2017 (4 pages). [cited by applicant]
First Office Action for Mexican Patent Application No. MX/a/2017/009730, dated Jul. 8, 2021 (6 pages). [cited by applicant]
Fischer et al., “The gel-forming polysaccharide of psyllium husk ( [cited by applicant]
Gietl et al., “Factors involved in the in vitro fermentability of short carbohydrates in static faecal batch cultures,” International Journal of Carbohydrate Chemistry. 2012:197809 (2012) (10 pages). [cited by applicant]
Gómez et al., “Purification, characterization, and prebiotic properties of pectic oligosaccharides from orange peel wastes,” J Agric Food Chem. 62(40):9769-82 (2014). [cited by applicant]
Hernot et al., “In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose,” J Agric Food Chem. 57(4):1354-61 (2009). [cited by applicant]
Holscher, “Dietary Fiber and Prebiotics and the Gastrointestinal Microbiota,” Gut Microbes. 8(2):172-184 (2017). [cited by applicant]
Houdijk et al., “Effects of dietary oligosaccharides on the growth performance and faecal characteristics of young growing pigs,” Anim Feed Sci Tech. 71:35-48 (1998). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/039795, mailed Oct. 7, 2015 (9 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/013265, mailed Mar. 11, 2016 (9 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/013271, mailed Mar. 11, 2016 (8 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/013280, mailed Mar. 21, 2016 (12 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/029082, mailed Oct. 14, 2016 (17 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/029083, mailed Oct. 14, 2016 (16 pages). [cited by applicant]
Kobata, “Structures and application of oligosaccharides in human milk,” Proc Jpn Acad Ser B Phys Biol Sci. 86(7):731-47 (2010) (17 pages). [cited by applicant]
Kodansha, Basis of Sugar Chemistry. 11th edition: 92-117 (1995). [cited by applicant]
Koropatkin et al., “How glycan metabolism shapes the human gut microbiota,” Nat Rev Microbiol. 10(5):323-35 (2012). [cited by applicant]
Kuechel et al., “Short communication: Development of a rapid laboratory method to polymerize lactose to nondigestible carbohydrates,” J Dairy Sci. 101(4): 2862-2866 (Apr. 2018) (5 pages). [cited by applicant]
Louis et al., “How to manipulate the microbiota: prebiotics,” Adv Exp Med Biol. 902:119-42 (May 2016). [cited by applicant]
Macfarlane et al., “Review Article: Prebiotics in the Gastrointestinal Tract,” Aliment Pharmacol Ther. 24(5):701-14, DOI: 10.1111/j. 1365-2036.2006.03042.x (2006). [cited by applicant]
Man et al., “Study on Cultivation and Cryoprotectant of Bifidobacterium Bifidum,” Data Knowledge Service Platform, 1-87 (2012) (5 pages). [cited by applicant]
Mora et al., “Synthetic Polysaccharides. V. Polymerization of Various Aldoses,” J Am Chem Soc. 82(13):3418-21 (1960). [cited by applicant]
Mountzouris et al., “Modeling of oligodextran production in an ultrafiltration stirred-cell membrane reactor,” Enzyme Microb Technol. 24(1): 75-85 (1999). [cited by applicant]
Office Action for Brazilian Patent Application No. BR112017015944-9, dated Nov. 10, 2019 (6 pages). [cited by applicant]
Office Action for Chinese Patent Application No. 201580048065.6, dated Oct. 31, 2018 (12 pages). [cited by applicant]
Office Action for Chinese Patent Application No. 201680016822.6, issued Apr. 24, 2020 (21 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2017-557271, mailed Feb. 18, 2020 (15 pages). [cited by applicant]
Office Action for Mexican Patent Application No. MX/a/2017/009730, dated Feb. 11, 2022 (13 pages). [cited by applicant]
Olano-Martin et al., “In vitro fermentability of dextran, oligodextran and maltodextrin by human gut bacteria,” Br J Nutr. 83(3):247-55 (2000). [cited by applicant]
Pfenninger et al., “Structural analysis of underivatized neutral human milk oligosaccharides in the negative ion mode by nano-electrospray MS(n) (part 2: application to isomeric mixtures),” J Am Soc Mass Spectrom. 13(11… [cited by applicant]
Product label for BMD 50, Bacitracin methylene disalicylate type A medicated article antibacterial, Zoetis (1 page), (retrieved in year 2021). [cited by applicant]
Roberfroid, “Prebiotics: the concept revisited,” J Nutr. 137(3 Suppl 2):830S-7S (2007). [cited by applicant]
Rodriguez-Colinas et al., “Galacto-oligosaccharide synthesis from lactose solution or skim milk using the beta-galactosidase from Bacillus circulans,” J Agric Food Chem. 60(25):6391-8 (2012). [cited by applicant]
Sanz et al., “Influence of glycosidic linkages and molecular weight on the fermentation of maltose-based oligosaccharides by human gut bacteria,” J Agric Food Chem. 54(26):9779-84 (2006). [cited by applicant]
Search Report for Russian Patent Application No. 2017130166/10(052504), mailed May 13, 2019 (4 pages). [cited by applicant]
Sharon, “Carbohydrates as future anti-adhesion drugs for infectious diseases,” Biochim Biophys Acta. 1760(4):527-37 (2006). [cited by applicant]
Si et al., “Quantification of cell proliferation and alpha-toxin gene expression of Clostridium perfringens in the development of necrotic enteritis in broiler chickens,” Appl Environ Microbiol. 73(21):7110-3 (2007). [cited by applicant]
Swennen et al., “Large-scale production and characterisation of wheat bran arabinoxylooligosaccharides,” J Sci Food Agric. 86(11):1722-31 (2006). [cited by applicant]
Synytsya et al., “Glucans from fruit bodies of cultivated mushrooms [cited by applicant]
Timbermont, et al., “Necrotic enteritis in broilers: an updated review on the pathogenesis,” Avian Pathol. 40(4):341-7 (2011). [cited by applicant]
Tomlin et al., “A comparative study of the effects on colon function caused by feeding ispaghula husk and polydextrose,” Aliment Pharmacol Therap. 2(6):513-9 (1988). [cited by applicant]
Torres et al., “Galacto-Oligosaccharides: Production, Properties, Applications, and Significance as Prebiotics,” Compr Rev Food Sci Food Saf. 9(5):438-54 (Sep. 2010). [cited by applicant]
Tremaine et al., “Polymerization of lactose by twin-screw extrusion to produce indigestible oligosaccharides,” International Dairy Journal. 36(1):74-81 (2014). [cited by applicant]
Tremaine, Andrea Jane, thesis: “Twin-Screw Extrusion of Commodity Grade Dairy Ingredients to Produce Value-Added Products,” Master of Science, The Graduate School of the University of Minnesota, 2012 (152 pages). [cited by applicant]
Velayudhan et al., “Characterization of Dietary Energy in Swine Feed and Feed Ingredients: A Review of Recent Research Results,” Asian-Australas J Anim Sci. 28(1):1-13 (Jan. 2015). [cited by applicant]
Wang et al., “Preparation and structural characterization of poly-mannose synthesized by phosphoric acid catalyzation under microwave irradiation,” Carbohydr Polym. 121:355-61 (May 2015). [cited by applicant]
Wang et al., “Rapid microwave-assisted synthesis of polydextrose and identification of structure and function,” Carbohydrate Polymers. 113:225-30 (2014). [cited by applicant]
Winfree et al., “Effects of Dietary Protein and Energy on Growth, Feed Conversion Efficiency and Body Composition of Tilapia aurea,” J. Nutr. 111(6):1001-1012 (1981). [cited by applicant]
Zeuner et al., “Methods for improving enzymatic trans-glycosylation for synthesis of human milk oligosaccharide biomimetics,” J Agric Food Chem. 62(40):9615-31 (2014). [cited by applicant]
van Leeuwen et al., “1H NMR analysis of the lactose/beta-galactosidase-derived galacto-oligosaccharide components of Vivinal® GOS up to DP5,” Carbohydr Res. 400:59-73 (Dec. 2014). [cited by applicant]
Brisson et al., “Solution conformation of asparagine-linked oligosaccharides: α(1-2)-, α(1-3)-, β(1- 2)-, and β(1-4)-linked units,” Biochemistry 22(15):3671-80 (Jul. 19, 1983). [cited by applicant]